Orbis Medicines, a leader in oral macrocycle drug discovery, has announced a strategic collaboration and license agreement with Novo Nordisk to discover and develop next-generation oral macrocycle therapeutics for cardiometabolic diseases. The agreement enables the acceleration of the development of a new class of orally available medicines for high-value therapeutic targets.
Under the terms of the agreement, Orbis Medicines is eligible to receive up to US$1.4 billion in upfront and potential development and commercial milestone payments, in addition to tiered royalties on future product sales. Novo will also make a strategic investment in Orbis Medicines, underscoring its confidence in the company’s nGen platform and long-term potential.
Latham & Watkins LLP represents Novo Nordisk in the transaction with a corporate team led by New York partner Aaron Gardner, with associate Arun Mohan.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
